Evaluation of the toxicity and hepatoprotective properties of new s-substituted pteridins
Curr Issues Pharm Med Sci., Vol. 36, No. 1, 21-26
Natalya Groma1
, Galyna Berest2, Oleksii Antypenko3*, Oleksii Voskoboinik4,
Vira Kopiika1, Serhii Kovalenko5, Volodymyr Shvets6*
1 Department of Physiology, Immunology, Biochemistry with a course in Civil Defense and Medicine, Zaporizhzhia National University, Ukraine
2 Department of Pharmacognosy, Pharmaceutical Chemistry and Medicinal Preparations Technology, Zaporizhzhia State Medical University, Ukraine
3 Department of Organic and Bioorganic Chemistry, Zaporizhzhia State Medical University, Ukraine
4 Department of Composite Materials, Chemistry and Technology, National University "Zaporizhzhia Polytechnic", Ukraine
5 Research Institute of Chemistry and Geology, Oles Honchar Dnipro National University, Ukraine
6 Department of Biological Chemistry, Zaporizhzhia State Medical University, Ukraine
10.2478/cipms-2023-0006
© 2023 Author(s). This is an open access article distributed under the Creative Commons Attribution-NonComercial-No Derivs licence (http://creativecommons.org/licenses/by-nc-nd/3.0/)
Abstract
Liver damage is a common problem around the world, and pharmacocorrection of such disease is carried out by administration of various drugs. Natural and synthetic thio-containing compounds are important in this respect. Most of these, however, have side effects and do not always meet the criteria of evidence-based medicine. Therefore, the search for new drugs with hepatoprotective properties, characterized by high efficiency and low toxicity, is an urgent problem of current pharmacology and biochemistry. The purpose of this study was to assess the acute toxicity of new potentially bioactive S-substituted pteridinones, to select the least toxic substance, to improve the pharmaco-technological characteristics, and to study the hepatoprotective properties in an experimental model of tetrachloromethane hepatitis in rats. Herein, comparison of the hepatoprotective properties of compound 4.1 and the reference drug "Thiotriazoline" is based on biochemical studies. The research results showed that sub-stance 4.1 had a positive effect on biochemical processes by increasing the compensatory mechanisms of antioxidant systems, while reducing the infiltrative, destructive and inflamma-tory process in the liver, evoking decreases in the cytolytic process, restoring the structure of the components of the membrane of hepatocytes, stabilizing and enhancing the functional activity of the liver, restoring the liver’s protein-synthesizing function and increasing the abil-ity to restore metabolic disorders in the liver. As a result of the biochemical study of the hepa-toprotective effect of compound 4.1, it was found that the studied substance is a non-toxic compound with antioxidant properties.
Full Text
Keywords
toxic liver damage, S-substituted pteridines, acute toxicity, hepatoprotective and antioxidant properties.
References
- Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;34(7): 757-66.
- Stine JG, Chalasani NP. Drug hepatotoxicity. Clin Liver Dis. 2017; 21(1):103-13.
- Timasheva GV, Bakirov AB, Mukhammadieva GF, Smolyankin DA, Khusnutdinova NY, Karimov DD. Evaluation of the effectiveness of the use of hepatoprotector in acute liver damage by various toxicants in the experiment. Hygiene and Sanitation. 2021;100(11):1292-7.
- Morellato AE, Umansky C, Pontel LB. The toxic side of one-carbon metabolism and epigenetics. Redox Biology.
- Rembold H, Gyure WL. Biochemistry of the pteridines. Angewandte Chemie International Edition in English. 1972;11(12):1061-72.
- Pfleiderer W. Pteridines. Second Supplements to the 2nd Edition of Rodd’s Chemistry of Carbon Compounds. 1991:269-330.
- Bi X, Li J, Li J, Shi W, Dai Y, Li Q, et al. Design, synthesis and biological evaluation of novel 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as potential BRD4 inhibitors. Bioorg Med Chem. 2019;27(13):2813-21.
- Ma F, Lü G, Zhou WF, Wang QJ, Zhang YH, Yao QZ. Synthesis and biological evaluation of 2,4-diaminopteridine derivatives as nitric oxide synthase inhibitor. Chin Chem Lett. 2009;20(4):420-2.
- Cavazzuti A, Paglietti G, Hunter WN, Gamarro F, Piras S, Loriga M, et al. Discovery of po-tent pteridine reductase inhibitors to guide antiparasite drug development. PNAS. 2008;105(5):1448-53.
- Corona P, Gibellini F, Cavalli A, Saxena P, Carta A, Loriga M, et al. Structure-based selec-tivity optimization of piperidine–pteridine derivatives as potent leishmania pteridine reductase inhibitors. J Med Chem. 2012;55(19):8318-29.
- Ghoneim AA, Ahmed Elkanzi NA, Bakr RB. Synthesis and studies molecular docking of some new thioxobenzo[g]pteridine derivatives and 1,4-dihydroquinoxaline derivatives with glycosidic moiety. JTUMED. 2018;12(6):774-82.
- Nosulenko IS, Kazunin MS, Kinichenko AO, Antypenko OM, Zhurakhivska LR, Vos-koboinik OY, et al. Dihydrofolate reductase inhibitors among pteridine and furo[3,2-g]pteridine derivatives. Biopolym Cell. 2021;37(2):143-52.
- Milstien S. Chemistry and biology of Pteridines and folates. Proceedings of the 12th International Symposium on pteridines and folates, National Institutes of Health, Bethesda, Maryland, June 17-22, 2001. Boston: Kluwer Academic Publishers; 2002.
- Abu-Hashem AA, El-Shazly M. Synthesis of new isoxazole-, pyridazine-, pyrimidopyrazines and their anti-inflammatory and analgesic activity. Med Chem. 2018;14(4):356-71.
- Kazunin M, Groma N., Nosulenko I., Kinichenko A., Antypenko O, Shvets V, Voskoboinik O., Kovalenko S. Тhio-containing pteridines: synthesis, modification and biological activity. Archiv der Pharmazie. 2022:e2200252.
- ProTox-II – Prediction of Toxicity of Chemicals. [https://tox-new.charite.de/protox_II/index.php?site=home.-do] (access: 11 May 2022)
- Kozhem'yakin YuM, Khromov OS, Filonenko MA. Scientific and practical recommendations for the development of laboratory creatures and robots. K.: Avitsena; 2002:156.
- Prozorovskiy VB, Prozorovskaya MP, Demchenko VM. Express method for determining the average effective dose and its errors. Farmakol Toxicol. 1978;4:497-502.
- European convention for the protection of vertebrate animals used for experimental and other scientific purposes. European Treaty Series. 1986; No. 123. Strasbourg: Council of Europe.
- Stefanov OV. Preclinical study of drugs (methodical recommendation). Kyiv: Avitsena; 2001.
- Morellato AE, Umansky C, Pontel LB. The toxic side of one-carbon metabolism and epigenetics. Redox Biology. 2021;40:101850.
- Mazur IA, Voloshin NA, Chekman IS. Thiotriazolin: pharmacological aspects and clinical application. Lvov: Zaporozhye; 2005;160.
- Gudyvok Ya, Kupnovitska IG, Golubeva MG Thiotriazolin: clinico-pathogenetic aspects in liver lesions. Herald Pharmacol Pharm. 2005; 7:7-9.
- Bhakuni GS, Bedi O, Bariwal J, Deshmukh R, Kumar P. Animal models of hepatotoxicity. Inflammation Res. 2015;65(1):13-24.
- Menshikov VV, Delektorskaya LN, Zolotnitskaya RP. Laboratory research methods in the clinic. Moskow: Medicine, 1987:386.
- Bergmeyer HU, Horder M and Rej R: International Federation of Clinical Chemistry (IFCC) Scientific Committee. Analytical section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentrations of enzymes. Part 3: IFCC Method for Alanine Aminotransferase (EC 2.6.1.2). J Clin Chem Clin Biochem. 1986;24:481-95.
- Вergmeyer HU, Horder M, Rej R. International Federation of Clinical Chemistry (IFCC) Scientific Committee. Analytical section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentrations of enzymes. Part 2. IFCC methods for the measurement of catalytic for aspirate aminotransferase (Lasparatate: 2- oxoglutarate aminotransferase, EC 2.6.1.1). J Clin Chem Clin Biochem. 1986;24:497-5103.
- Gutmann I, Bergmeyer H.U. Methods of enzymatic Analysis. New York: Academic Press;1974:1794-8.
- Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the Biuret reaction. J Biol Chem. 1949;177(2): 751-66.
- Bertis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemestry and Molecular Diagnostics. 4th ed. WB Saunders Co; 2005.
- Muller G., Fruhant A., Mathias B. Thiobarbiturasure-positive substanzen als indikatoren der lipid peroxidation. Gzamte Um Med Grenzgeb. 1986;41(24);673-6.
- Korolyuk MA, Ivanova, AI, Mayorova IG, Tokarev VE. Metod opredeleniya aktivnosti kata-lazy. Lab Delo Laboratory Case. 1988;1, 16-19.
- Best F. Uber Karminfarbung des Glykogens und der Kerne. Z Wiss. Mikr. 1906;23:319.
- Stefanov OV. Preclinical study of drugs (methodical recommendation). Kyiv: Avitsena; 2001.
- Yousefi‐Manesh H, Shirooie S, Partoazar A, Nikoui V, Estakhri MR, Bakhtiarian A. Hepato-protective effects of phosphatidylserine liposomes on carbon tetrachloride‐induced hepatotox-icity in rats. J Cell Biochem. 2019;120(7):11853-8.
- Aslanian MA, Bobrytska LA, Bereznyakova NL, Shpychak OS, Hrytsenko VI, Germanyuk TA, et al. Biochemical research of hepatoprotective activity of Lavaflam tablets in rats with subchronic hepatitis. Curr Issues Pharm Med Sci. 2020;33(1):10-3.
- D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol. 2006;44(1):217-31.
- Toxicological profile for carbon tetrachloride – agency for toxic. [https://www.atsdr.cdc.gov/toxprofiles/tp30.pdf] (access: 4 November 2022)
- Abouzied MM, Mahmoud SM, Wahid A, Ahmed AE, Okasha AM, Soliman HA, et al. A study of the hepatoprotective effect of plantago psyllium L. Seed extract against carbon tetra-chloride induced hepatic injury in rats. J Appl Biomed. 2020;18(2-3):80-6.
- Abramov SS. Lipid peroxidation and endogenous intoxication in animals, ways of correction: monograph. Vitebsk: UO VGAVM; 2007:208.
- Lee C-H, Park S-W, Kim YS, Kang SS, Kim JA, Lee SH, et al. Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice. Biol Pharm Bull. 2007;30(10): 1898-904.
